Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape. Report reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Agency -.
ReportsnReports.com latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.
Report with Complete TOC Available at www.reportsnreports.com/reports/958306-friedreich-ataxia-pipeline-review-h1-2017.html
Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family.
Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.
- Agency -.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 13 and 3 respectively.
Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.